Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial

After a review of clinical data from the Generation Program studies, Novartis, Amgen and Banner Alzheimer’s Institute have decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program.

July 12th, 2019|News|

FDA approval for Novartis’ Piqray

Novartis’ Piqray (alpelisib) has been approved by the US Food and Drug Administration (FDA) in combination with fulvestrant for the treatment of postmenopausal women and men with HR+ and HER2- PIK3CA-mutated, advanced or metastatic breast cancer.

May 28th, 2019|News|

Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

Novartis has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide.

May 14th, 2019|News|

New data reinforce effectiveness of Novartis’ Zolgensma for SMA

New AveXis data has reinforced the effectiveness of Novartis’ spinal muscular atrophy (SMA) Type I drug, Zolgensma (onasemnogene abeparvovec-xioi).

April 17th, 2019|News|